HMGB1 has since been identified as a pathogenic mediator during sepsis, arthritis, cancer, drug-induced liver injury and stroke, among other diseases, and inhibition of HMGB1 is beneficial in several experimental models (Andersson and Tracey 2011). The gene discussed is HMGB1; the disease is stroke disorder.